Michael Wang, MD

Moruf A, Spyropoulos AC, Schardt TQ, Gibson E, Manco-Johnson MJ, Wang M and Goldenberg NA. Peri-procedural bridging with low molecular weight heparin in patients receiving warfarin for venous thromboembolism: A pediatric experience. Thromb Res. 2012;130(4):612-5.

Hancock HS, Wang M, Gist K, Miyamoto S, Manco-Johnson MJ and Neil Goldenberg NA. Cardiac Findings and Long-Term Thromboembolic Outcomes Following Pulmonary Embolism in Children: A Combined Retrospective-Prospective Inception Cohort Study. Cardiol Young. 2012;22:1-9.

Ng C, Silliman CC, Smith W, Pearl G, Manco-Johnson MJ and Wang M. Treatment of refractory hemorrhage with factor XIII in a hemophilia A patient with inhibitor. Pediatr Blood Cancer.

Hancock HS, Wang M, Gist K, Miyamoto S, Manco-Johnson MJ and Neil Goldenberg NA. Cardiac Findings and Long-Term Thromboembolic Outcomes Following Pulmonary Embolism in Children: A Combined Retrospective-Prospective Inception Cohort Study. Cardiol Young. 2013;22(3):344-52.

Ng C, Silliman CC, Smith W, Pearl G, Manco-Johnson MJ and Wang M. Treatment of refractory hemorrhage with factor XIII in a hemophilia A patient with inhibitor. Pediatr Blood Cancer. 2013;60(7):E23-5.

Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK. Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types. J Immunol. 2013;191(9):4880-8.

Onasoga AA, Leiderman K, Fogelson AL, Wang M, Manco-Johnson MJ, Di Paola JA and Neeves KB. The effect of FVIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models. PLOS ONE. 2013;8(11):e78732.

Kesselheim J, Atlas M, Adams D, Aygun B, Barfield R, Eisenman K, Fulbright J, Kersun L, Nageswara Rao A, Sharma M, Shereck E, Wang M and Leavey P. Humanism and Professionalism for Pediatric Hematology-Oncology Fellows (HP-PHO). MedEdPORTAL;Publication ID 9607:2013.

Wang M, Bajaj L, Miyamoto S, Fenton L and Mourani P. Multidisciplinary Working Group for Thrombosis and Stroke Care Pathways. Pulmonary Embolism (Suspected Acute) in Children: Diagnostic Evaluation and Management

Hoffman, LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V, Hemenway MS, Liu AK, Wang M, Hankinson TC, Handler MH and Foreman NK. Molecular sub-group specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol. 2013 (Epub ahead of print).

Ambruso DR, Wang M and Nuss R. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 22nd Edition.

Wang M and Williams S. Pulmonary Embolism. In: Goldenberg NA and Manco-Johnson MJ (eds.): Pediatric Venous Thromboembolism.

Cho H, Wang M, DiPaola J, Dienhart M and Hays T. Bleeding clinic as a valid screening clinic for clinically significant bleeding disorders. 25th Annual Meeting of the American Society of Pediatric Hematology-Oncology. 2013. Miami, FL.

Onasoga AA, Leiderman K, Fogelson AL, Wang M, Manco-Johnson MJ, Di Paola JA and Neeves KB. The role of factor VIII deficiency and factor VIIa bypass treatment in modulating the dynamics of thrombin and fibrin generation under flow. Biomedical Engineering Society (BMES) Annual Meeting. 2013. Seattle, Washington.

Ng CJ, McCrae KR, Chen J, Wang M, Manco-Johnson M, White-Adams TC, López JA and Di Paola J. Antiphospholipid antibodies increase Von Willebrand Factor-platelet string formation from human endothelial cells under physiologic flow conditions. 55th Annual Meeting of the American Society of Hematology. 2013. New Orleans, LA.

Wang M, Schardt TQ, DiStefano MC and Pickard D. Clinical Care Guideline: Hemophilia Emergencies Clinical Care Guideline. Children’s Hospital Colorado, Aurora, CO. 2013.

Carpenter RB, Wang M, Branham D, Zeitler P, Gottlieb P and Lovell MA. Policy and Procedure: Blood Draw Volumes, Maximum. Children’s Hospital Colorado, Aurora, CO. 2013.

Poppy A, Pickard D, Schardt TQ, Fisher F, Davidson J and Wang M (Anticoagulation Safety Committee). Anticoagulation Dosing and Monitoring Protocols. Children’s Hospital Colorado, Aurora, CO. Revised 2013.

Wang M, Bajaj L, Miyamoto S, Fenton L and Mourani P. Multidisciplinary Working Group for Thrombosis and Stroke Care Pathways. Suspected Acute Lower Extremity Deep Vein Thrombosis (DVT) Involving a Proximal Limb. Children’s Hospital Colorado, Aurora, CO. Revised 2013.

Wang M, Bajaj L, Miyamoto S, Fenton L and Mourani P. Multidisciplinary Working Group for Thrombosis and Stroke Care Pathways. Pulmonary Embolism (Suspected Acute) in Children: Diagnostic Evaluation and Management Pathway. Children’s Hospital Colorado, Aurora, CO. Revised 2013.

Hoffman, LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V, Hemenway MS, Liu AK, Wang M, Hankinson TC, Handler MH and Foreman NK. Molecular sub-group specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol. 2014;127(5):731-45.

Smith C, Lee-Miller C, MD, Dishop M, Wang M, Cost C and Edwin J. Asturias. Multicentric Castleman’s Disease Presenting as Fever of Unknown Origin in a Young Child. J Pediatr. 2014;165(6):1261-5.

Ambruso DR, Nuss R and Wang M. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 23nd Edition. 2014.

Wang M and Williams S. Pulmonary Embolism. In: Goldenberg NA and Manco-Johnson MJ (eds.): Pediatric Venous Thromboembolism. Cambridge University Press, Cambridge, UK. 2014.

Berrios C, Jung J, Primi B, Wang M, Pedamallu C, Fujiko Duke F, Jingwei Cheng, Robert L. Garcea RL, Matthew Meyerson M, James A. DeCaprio JA and the TEDDY Study Group. Malawi polyomavirus is a prevalent human virus and interacts with known tumor suppressors. J Virol. 2015;89(1):857-62.

Kesselheim J, Atlas M, Adams D, Aygun B, Barfield R, Eisenman K, Fulbright J, Garvey K, Kersun L, Nageswara Rao A, Reilly A, Sharma M, Shereck E, Wang M, Watt T and Leavey P. Humanism and Professionalism Education for Pediatric Hematology-Oncology Fellows: A Model for Pediatric Subspecialty Training. Pediatr Blood Cancer. 2015;62(2):335-340.

Smith NL, Onasoga A, Jacobson L, Villalobos-Menuey E, Ruegg KA, Wang M and Manco-Johnson MJ. Thromboelastography (TEG) as a global assay to elucidate complex nuances of hemostasis in pediatric inhibitor patients with high titer inhibitors. 56th Annual Meeting of the American Society of Hematology. 2014. San Francisco, CA.

Lee-Miller CA, Smith C, Wang M, Dishop M, Hayes K, Asturias E and Cost C. Treatment of an atypical case of hyaline vascular variant multicentric Castleman’s disease. 27th Annual Meeting of the American Society of Pediatric Hematology/Oncology. 2014. Chicago, IL.

Ng CJ, McCrae KR, Chen J, Wang M, Manco-Johnson M, White-Adams TC, López JA and Di Paola J. Human anti-ß2-GPI antibodies increase the release of soluble and cell surface anchored Von Willebrand Factor from human endothelial cells. Thrombosis & Hemostasis Summit of North America. 2014. Chicago, IL.

Ambruso DR, Nuss R and Wang M. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 23rd Edition. McGraw-Hill Education, Lange. 2016.

Wang M, Álvarez Román MT, Chowdary P, Quon DV and Schafer K. Physical Activity in Individuals with Haemophilia and Experience with rFVIIIFc and rFIXFc for the Treatment of Active Patients: A Literature Review and Case Reports. Blood Coagulation and Fibrinolysis. 2016 Jun 7. [Epub ahead of print].

Buckner TW, Andrew D. Leavitt AD, Ragni M, Kempton CL, Eyster E, Cuker A, Lentz SR, Ducore J, Mark T. Reding, Cindy Leissinger, Wang M and Key NS. Prospective, Multicenter Study of Postoperative Deep Vein Thrombosis in Patients with Hemophilia Undergoing Major Orthopedic Surgery. Thromb Haemost. 2016;116(1).

Rogers AE, Eisenman KM, Dlan S, Belderson KM, Zauche JR, Tong S, Gralla J, Hilden JM, Wang M, Maloney KW and Domiguez SR. Risk Factors for Central Line Associated Blood Stream Infections in Children with Acute Myelogenous Leukemia: A Single Institution Report. Pediatr Blood Cancer. 2016 Sep 12. doi: 10.1002/pbc.26254. [Epub ahead of print]

Kesselheim JC, Agrawal A, Bhatia N, Cronin A, Jurban R, Kent P, Kersun L, Nageswara A, Rose M, Savelli S, Sharma M, Shereck E, Twist C and Wang M. Measuring pediatric hematology-oncology fellow’s skills in humanism and professionalism: a novel assessment. Pediatr Blood Cancer. 2016 Nov 3. doi: 10.1002/pbc.26316. [Epub ahead of print]

John Pasi K, Pabinger-Fasching I, Kerlin B, Kulkarni R, Nolan B, Wang M, , Liesner R, Hanabusa H, Tsao E and Allen G Long-Term Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Paediatric, Adolescent, and Adult Subjects with Target Joints and Severe Haemophilia A. 9th Annual Congress of the European Association of Haemophilia and Allied Disorders. 2016. Malmo, Sweden.

Wang M, Cyhanuik A, Cooper D and Iyer NN. Identification of Persons with Acquired Hemophilia in a Large Electronic Health Record Database. ISPOR 21th Annual International Meeting. 2016. Washington, D.C.

Witkop M, Neff A, Buckner T, Wang M, Batt K, Kessler C, Quon D, Boggio L, Recht M, Baumann K, Cooper DL and Kempton C,. Self-Reported Prevalence, Description, and Management of Pain in Adult People With Hemophilia (PWH) From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Thrombosis & Hemostasis Summit of North America. 2016. Chicago, IL.

Abraham S, Winter S and Wang M. Between a rock and a hard place: Treating severe hemophilia A with high titer inhibitor and allergy to factor VIII product. Regional Meeting of the Hemophilia Treatment Center Network Regions VIII/IX/X. 2016. Scottsdale, AZ.

Wang M, Álvarez Román MT, Chowdary P, Quon DV and Schafer K. Physical Activity in Individuals with Haemophilia and Experience With rFVIIIFc and rFIXFc for the Treatment of Active Patients: A Literature Review and Case Reports. Blood Coagulation and Fibrinolysis (in press).

Wang M, Batt K, Kessler C, Neff A, Iyer N, Cooper DL and Kempton C. Internal Consistency and Item-Total Correlation of Patient-Reported Outcome (PRO) Instruments and Hemophilia Joint Health Score v2.1 (HJHS) in US Adult People With Hemophilia (PWH): Results From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. 62nd Annual SSC Meeting of the International Society on Thrombosis and Haemostasis. 2016. Montpellier, France.

Buckner TW, Wang M, Copoer DL and Kempton C. Known-Group Validity of Patient-Reported Outcome (PRO) Instruments and Hemophilia Joint Health Score v2.1 (HJHS) in US Adult People With Hemophilia (PWH): Results From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. 62nd Annual SSC Meeting of the International Society on Thrombosis and Haemostasis. 2016. Montpellier, France.

Ambruso DR, Nuss R and Wang M. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 24nd Edition. (in press)

Hernandez G, Baumann K, Recht M, Neff A, Quon D, Kessler C, Wang M, Buckner TW, Boggio L, Cooper DL and Kempton C. Hemophilia Joint Health Score v2.1 (HJHS) in US Adult People With Hemophilia (PWH) in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. XXXII International Congress of the World Federation of Hemophilia. 2016. Orlando, FL.

Wang M and Williams S. Pulmonary Embolism. In: Goldenberg NA and Manco-Johnson MJ (eds.): Pediatric Venous Thromboembolism. Cambridge University Press, Cambridge, UK. 2015.

Witkop M, Hernandez G, Recht M, Wang M, Baumann K, Cooper DL and Kempton C. Assessments of Functional Impairment in US Adults with Hemophilia Across Patient-Reported Outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. XXXII International Congress of the World Federation of Hemophilia. 2016. Orlando, FL.

Multicenter Randomized Controlled Trial on Duration of Therapy for Thrombosis in Children (Kids-DOTT): Findings from the Pilot-Feasibility Phase. J Thromb Haemost (in press).

Wang M, Lawrence J, Burggraff J, Ducore J, Simpson M, Stevens J and Freiling J. A Phase Ib, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Coagulation Factor VIIa in Congenital Hemophilia A or B. XXXII International Congress of the World Federation of Hemophilia. 2016. Orlando, FL.

Wang M, Quon DV, Lawrence J, Redding M, Ducore J, Simpson M, Boggio L, Freiling J Alexander W and Schved J. The Global, Multi-Center, Phase III, Randomized, Efficacy, Pharmacokinetic and Safety Cross-Over Study (PERSEPT 1) of Two Dose Regimens of Eptacog Beta (rhFVIIa) in Congenital Hemophilia A and B Patients with Inhibitors to Factor VIII or IX (HABI). XXXII International Congress of the World Federation of Hemophilia. 2016. Orlando, FL.

Wang M, Pasi KJ, Pabinger I, Kerlin BA, Kulkarni R, Nolan B, Liesner R, Brown SA, Hanabusa H, Tsai E, Winding B, Lethagen S and Jain N. Long-term Efficacy and Quality of Life With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A. 58th Annual Meeting of the American Society of Hematology. 2016. San Diego, CA.

Mahlangu J, Weldingh KN, Lentz SR, Kaicker S, Abdul Karim F, Matsushita T, Recht M, Tomczak T, Windyga J, Ehrenforth S, Knobe, K on behalf of the adeptTM2 investigators. Changes in the amino acid sequence of the rFVIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost (in press).

Kesselheim J, Atlas M, Adams D, Aygun B, Barfield R, Eisenman K, Fulbright J, Garvey K, Kersun L, Nageswara Rao A, Reilly A, Sharma M, Shereck E, Wang M, Watt T and Leavey P. Humanism and Professionalism Education for Pediatric Hematology-Oncology Fellows: A Model for Pediatric Subspecialty Training. Pediatr Blood Cancer. 2015;62(2):335-340.

Batt K, Recht M, Wang M, Quon D, Boggio L, Kessler C, Buckner TW, Neff A, Iyer N, Cooper DL and Kempton CL. Linear and Logistic Regression Models of Patient-Reported Outcomes and Patient Characteristics in US Adults With Hemophilia From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. 58th Annual Meeting of the American Society of Hematology. 2016. San Diego, CA.

Warren B, Smith N, Blades T, Wang M and Manco-Johnson M. Break-thru bleeding in patients with Hemophilia A on prophylaxis. 58th Annual Meeting of the American Society of Hematology. 2016. San Diego, CA.

Knight-Perry J, Towler E, Payan M, Branchford B, Martiniano SL, Sagel SD and Wang M. Venous Thromboembolism in Pediatric Cystic Fibrosis. 58th Annual Meeting of the American Society of Hematology. 2016. San Diego, CA.

Kessler C, Meijer K, Armstrong A, Bichler J, Knaub S, Pezeshki G and Wang M. Individualized prophylaxis with Nuwiq (Human-cl rhFVIII) in adult PTPs with severe haemophilia A. 2017. 61st Annual Meeting of the Society of Thrombosis and Hemostasis Research. 2017. Basel, Switzerland.

Wang M, Quon D, Witkop M, Recht M, Iyer NN and Cooper DL. Patient Reported Outcomes and Joint Status Across Subgroups of US Adults With Hemophilia With Varying Patient Characteristics: Results From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Hemostasis and Thrombosis Research Society Research Symposium. 2017. Scottsdale, AZ.

Kessler C, Boggio L, Bichler J, Pezeshki G, Wang M and Ducore J. Individualized prophylaxis with Nuwiq (Human-cl rhFVIII) in adult PTPs with severe haemophilia A. 2017. Hemostasis and Thrombosis Research Society Research Symposium. 2017. Scottsdale, AZ.

Elias ER, Zeitler P and Wang M. Value of updated genetic testing: a case report. 2017. American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. Phoenix, AZ.

Berrios C, Jung J, Primi B, Wang M, Pedamallu C, Fujiko Duke F, Jingwei Cheng, Robert L. Garcea RL, Matthew Meyerson M, James A. DeCaprio JA and the TEDDY Study Group. Malawi polyomavirus is a prevalent human virus and interacts with known tumor suppressors. J Virol. 2015;89(1):857-62.

Rogers AEJ, Eisenman KM, Dolan SA, Belderson KM, Zauche JR, Tong S, Joanne M. Hilden JM, Wang M, Maloney KW and Dominguez SR. Abstract: Risk factors for central line associated blood stream infections in children with acute myelogenous leukemia: A single institution report. 28th Annual Meeting of the American Society of Pediatric Hematology/Oncology. 2015. Phoenix, AZ.

Kesselheim J, Bhatia N and Cronin A for the Collaborative Group of Pediatric Hematology-Oncology Fellowship Program Directors. Measuring Pediatric Hematology-Oncology Felows’ Skill in Humanism and Professionalism: A Novel Assessment Instrument. 28th Annual Meeting of the American Society of Pediatric Hematology/Oncology. 2015. Phoenix, AZ.

Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 23rd Edition. McGraw-Hill Education, Lange.

Rogers AE, Eisenman KM, Dlan S, Belderson KM, Zauche JR, Tong S, Gralla J, Hilden JM, Wang M, Maloney KW and Domiguez SR. Risk Factors for Central Line Associated Blood Stream Infections in Children with Acute Myelogenous Leukemia: A Single Institution Report. Pediatr Blood Cancer. 2017;64(3)1-7.

Kesselheim JC, Agrawal A, Bhatia N, Cronin A, Jurban R, Kent P, Kersun L, Nageswara A, Rose M, Savelli S, Sharma M, Shereck E, Twist C and Wang M. Measuring pediatric hematology-oncology fellow’s skills in humanism and professionalism: a novel assessment. Pediatr Blood Cancer. 2017;64(5):1-9.

Witkop M, Neff A, Buckner TW, Wang M, Batt K, Kessler CM, Quon D, Boggio L, Recht M, Baumann K, Gut RZ, Cooper DL and Kempton C. Self-Reported Prevalence, Description, and Management of Pain in Adults With Hemophilia: Methods, Demographics, and Results From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Haemophilia. 2017;23(4):556-565.

Wang M, Lawrence JB, Quon DV, Ducore J, Simpson M, Boggio L, Mitchell I, Yuan G, Alexander WA and Schved J. Eptacog Beta Demonstrates Dose-Dependent Efficacy and Safety and Supports Individualized Treatment for Inhibitor-Related Hemorrhage. Haemophilia. 2017;23(6):832-843.

Kempton C, Wang M, Recht M, Neff A, Shapiro A, Buckner T, Kulkarni R, Nugent D, Batt K, Wisniewski T and Cooper D. Pain Functional Impairment and Quality of Life (P-FIQ): An assessment of reliability of five patient reported outcome (PRO) instruments in adult people with hemophilia (PWH). ISPOR 20th Annual International Meeting. 2015. Philadelphia, PA.

Wang M, Cyhanuik A, Cooper D and Iyer NN. Identification of Persons with Acquired Hemophilia in a Large Electronic Health Record Database. J Blood Med. 2017;8:89-97.

Ducore J, Lawrence JB, Simpson M, Boggio L, Bellens A, Burggraff J, Stevens J, Moerland M, Freiling J and Wang M. Safety and Dose-Dependency of Eptacog Beta (Activated) in a Dose Escalation Study of Non-Bleeding Congenital Haemophilia A or B, With or Without Inhibitors. Haemophilia. 2017;23(6);844-851.

Knight-Perry J, Branchford BR, Thornhill D, Martiniano SL, Sagel SD and Wang M. Venous Thromboembolism in Children with Cystic Fibrosis: Incidence and Intrapopulation Risk Factors. Thromb Res. 2017;158:161-166.

Wang M, Cyhanuik A, Cooper D and Iyer NN. Identification of Persons with Congenital Hemophilia in a Large Electronic Health Record Database. J Blood Med. 2017;8;131-139.

Bauman K, Akins S, Funk S, Hernandez G, Kempton C, Wang M, Buckner T, and Cooper DL. Functional Impairment, Pain, and Pain Management in US Adult People With Hemophilia (PWH): Initial Lessons From the Pain, Functional Impairment, and Quality of Life (P-FIQ) Study. 14th WFH International Musculoskeletal Congress. 2015. Belfast, Ireland.

Wang M, Bauman K, Akins S, Funk S, Hernandez G, Kempton C, Buckner T, and Cooper DL. Pain, Functional Impairment, and Quality of Life (P-FIQ): Reliability of Patient Reported Outcome (PRO) Instruments Assessing Pain and Function in US Adult People with Hemophilia (PWH). 14th WFH International Musculoskeletal Congress. 2015. Belfast, Ireland.

Nolan B, Young G, Rangarajan S, Wang M, Kerlin B, Leung A, Tsao E, Glazebrook D, Pierce GF and Allen GA. Analysis of Bleeding Rates in Paediatric subjects with target joints and severe haemophilia A receiving prophylaxis with recombinant factor VIII Fc fusion protein (rFVIIIFc) in Kids A-LONG. XXV Congress of the International Society on Thrombosis and Haemostasis. 2015. Toronto, Canada.

Buckner T, Witkop M, Wang M, Recht M, Batt K, Cooper DL and Kempton C. Prevalence, description and management of pain in adult people with hemophilia (PWH): Initial lessons from the Pain Functional Impairment and Quality of Life (P-FIQ) Study. XXV Congress of the International Society on Thrombosis and Haemostasis. 2015. Toronto, Canada.

Kempton CL, Wang M, Recht M, Neff A, Shapiro A, Soni A, Kulkarni R, Buckner TW, Batt K, Iyer NN and Cooper DL. Reliability of Patient-Reported Outcome Instruments in US Adult People with Hemophilia (PWH): The Pain, Functional Impairment and Quality of Life (P-FiQ) Study. Patient Prefer Adherence. 2017;11:1603-1612.

Wang M, Batt K, Kessler CM, Neff A, Iyer NN, Cooper DL and Kempton CL. Internal Consistency and Item-Total Correlation of Patient-Reported Outcome (PRO) Instruments and Hemophilia Joint Health Score v2.1 (HJHS) in US Adult People with Hemophilia (PWH): Results From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Patient Prefer Adherence. 2017;11:1831-1839.

Buckner TW, Wang M, Cooper DL, Iyer NN and Kempton CL. Known-Group Validity of Patient-Reported Outcome (PRO) Instruments and Hemophilia Joint Health Score v2.1 (HJHS) in US Adult People with Hemophilia (PWH): Results From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Patient Prefer Adherence. 2017;11:1745-1753.

Wang M, Neff A, Shapiro A, Kulkarni R, Reding M, Kuriakose P, Kessler C, Witkop M, Kempton C and Cooper DL. Reliability of patient-reported outcome (PRO) instruments in US adult people with hemophilia (PWH): The Pain Functional Impairment and Quality of Life (P-FIQ) Study. XXV Congress of the International Society on Thrombosis and Haemostasis. 2015. Toronto, Canada.

Kempton C, Recht M, Neff A, Wang M, Buckner TW, Amit S, Quon D, Witkop M, Boggio L, Gut R and Cooper DL. Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ). Haemophilia (in press)

Kessler C, Meijer K, Armstrong A, Bichler J, Knaub S, Pezeshki G and Wang M. Individualized prophylaxis with Nuwiq (Human-cl rhFVIII) in adult PTPs with severe haemophilia A. 2017. 61st Annual Meeting of the Society of Thrombosis and Hemostasis Research. 2017. Basel, Switzerland.

Wang M, Quon D, Witkop M, Recht M, Iyer NN and Cooper DL. Patient Reported Outcomes and Joint Status Across Subgroups of US Adults With Hemophilia With Varying Patient Characteristics: Results From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Hemostasis and Thrombosis Research Society Research Symposium. 2017. Scottsdale, AZ.

Kessler C, Boggio L, Bichler J, Pezeshki G, Wang M and Ducore J. Individualized prophylaxis with Nuwiq (Human-cl rhFVIII) in adult PTPs with severe haemophilia A. Hemostasis and Thrombosis Research Society Research Symposium. 2017. Scottsdale, AZ.

Elias ER, Zeitler P and Wang M. Value of updated genetic testing: a case report. 2017. American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. Phoenix, AZ. (492)

Kempton C, Recht M, Neff A, Wang M, Buckner T, Nugent D, Quon D, Witkop M, Boggio L and Cooper DL. Impact of pain and functional impairment in US adult people with hemophilia (PWH): Results from retest population in the Pain Functional Impairment and Quality of Life (P-FIQ) Study. XXV Congress of the International Society on Thrombosis and Haemostasis. 2015. Toronto, Canada.

Mahlangu J, Lepatan M, Vilchevska K, Oldenburg J, Stasyshyn O, Fischer K, Iosava G, Khayat C, Simpson M, Wang M, Bensen-Kennedy D, France N, St. Ledger K, Limsakun T and Pabinger I for the AFFINITY Study Group. rVIII-SingleChain Pharmacokinetics in Adults, Adolescents and Children. XXV Congress of the International Society on Thrombosis and Haemostasis. 2015. Toronto, Canada.

Pasi KJ, Pabinger I, Wang M, Kerlin BA, Kulkarni R, Nolan B, Liesner R, Brown SA, Tsao E, Winding B, Lethagen S and Jain N. Long-Term Health Outcomes with rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A. XXVI Congress of the International Society on Thrombosis and Haemostasis. 2017. Berlin, Germany.

Simpson M, Stasyshyn O, Fischer K, Oldenburg J, Alvarez Roman MT, Lambert T and Wang M. Dosing of rVIII-SingleChain Based on Clinical Bleeding Phenotypes Results in Low Bleeding Rates in Pediatric Patients Treated with Prophylaxis Two or Three times Weekly. XXVI Congress of the International Society on Thrombosis and Haemostasis. 2017. Berlin, Germany.

Wang M, Nolan B, Young G, Rangarajan S, Kerlin B, Kulkarni R, Ragni MV, Baker RI, Pasi KJ, Manco-Johnson MJ, Tsao T, Glazebrook D, Pierce GF, Allen G. Low Annualized Bleeding Rates in Phase 3 Studies of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects with Target Joints at Baseline. 67th Annual Meeting of the National Hemophilia Foundation: CRCT16. 2015. Dallas, Texas.

Kessler C, Shima M, Armstrong A-E, Bichler J, Sigurd K, Pezeshki G, Wang M and Ducore J. Pharmacokinetic guided personalized prophylaxis with Human-cl rhFVIII in adult patients with severe hemophilia A. XXVI Congress of the International Society on Thrombosis and Haemostasis. 2017. Berlin, Germany.

Forsberg A, Malouin R, Thornberg C, Oldfeld D, Wang M, Casto L, Hill J,Godfrey and Aschman D. National Quality Improvement Program on Transition from Pediatric to Adult Care: Evaluation of the first US pilot program. XXVI Congress of the International Society on Thrombosis and Haemostasis. 2017. Berlin, Germany.

Witkop M, Hernandez G, Recht M, Wang M, Baumann K, Cooper DL and Kempton C. Lessons Learned in the Assessment of Functional Status in US Adults with Hemophilia in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study: Importance of More Formalized Assessment of Function in the Comprehensive Care Setting. 69th Annual Meeting of the National Hemophilia Foundation. 2017. Chicago, IL.

Malec L, Kulkarni R, Sidonio RF, Wang M, Rodriguez N, Lethagen S, Glazebrook D and Jain Nisha. Study design for rFVIIIFc (ELOCTATE) ITI Study: A global, multicenter, open-label, interventional study evaluating rFVIIIFc for initial ITI therapy. 69th Annual Meeting of the National Hemophilia Foundation. 2017. Chicago, IL.

Pasi KJ, Pabinger I, Wang M, Kerlin BA, Kulkarni R, Nolan B, Liesner R, Brown SA, Tsao E, Winding B, Lethagen S and Jain N. Long-Term Impact of rFVIIIFc Prophylaxis in Paediatric, Adolescent, and Adult Subjects with Target Joints and Severe Haemophilia A. Haematology Society of Australia and New Zealand, Australian & New Zealand Society of Blood Transfusion and the Australasian Society of Thrombosis and Haemostasis (HAA) Annual Scientific Meeting. 2017. Sydney, Australia.

Wang M, Recht M, Iyer N, Cooper D and Soucie JM. The Relationship of Joint Range of Motion to Factor Activity in Patients withHemophilia a and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset. 59th Annual Meeting of the American Society of Hematology. 2017. Atlanta, GA. *Highlights of ASH

Witkop M, Baumann K, Buckner T, Akins S, Funk S, Hernandez G, Recht M, Wang M, Batt K, Kempton C and Cooper DL. Description and Management of Pain and Functional Impairment in US Adults With Hemophilia: Initial Observations From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. 67th Annual Meeting of the National Hemophilia Foundation. 2015. Dallas, Texas.

Buckner T, Wang M, Recht M, Baumann K, Witkop M, Akins S, Neff A, Funk S, Hernandez G, Nugent D, Kempton C, Quon D and Cooper DL. Initial Observations From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study: Patient-Reported Outcome Assessments in US Adults With Hemophilia. 67th Annual Meeting of the National Hemophilia Foundation: QLOR02. 2015. Dallas, Texas.

Warren BB, LeBlanc A, Wang M, Ng C, Branchford BR, Buckner T and Manco-Johnson M. Inhibitor Screening in Severe Hemophilia A: A Six-Year Single Center Experience. 59th Annual Meeting of the American Society of Hematology. 2017. Atlanta, GA.

Manco-Johnson MJ, Soucie MJ, Sharathkumar A, Bethea F, Kempton C, Payne AB, Wang M and Miller CH. Incidence of New-onset Elevated Inhibitor Titers Among Males with Hemophilia in the United States Hemophilia Treatment Center Network (USHTCN), December 15, 2013 – December 31, 2017. 59th Annual Meeting of the American Society of Hematology. 2017. Atlanta, GA.

Wang M, Konkle BA, Sidonio R, Flood V, Koenig C and Kulkarni R. Von Willebrand Disease Outreach into Integrated Care Education (VOICE): a call to action. Haemophilia. 2017;23(4):370-373.

Smith NL, Onasoga A, Jacobson L, Villalobos-Menuey E, Ruegg KA, Wang M and Manco-Johnson MJ. Thromboelastography (TEG) as a Global Assay to Elucidate Complex Nuances of Hemostasis in Pediatric Inhibitor Patients with High Titer Inhibitors. 57th Annual Meeting of the American Society of Hematology. 2015. Orlando, FL.

Wang M, Cyhanuik A, Cooper D and Iyer NN. Identification of Persons with Acquired Hemophilia in a Large Electronic Health Record Database. 57th Annual Meeting of the American Society of Hematology. 2015. Orlando, FL.

Malec L, Kulkarni R, Sidonio RF, Wang M, Rodriguez N, Lethagen S, Tsao E, Glazebrook and Jain N. Study design for verITI-8 Study: A global, multicenter, open-label, interventional study evaluating rFVIIIFc for initial ITI therapy. 11th Annual Congress of the European Association of Haemophilia and Allied Disorders. 2018. Madrid, Spain.

Abraham SM and Wang M. Treating a child with severe hemophilia A with high titer inhibitor and allergy to factor VIII product. 2nd International Conference on Inhibitors in Coagulation Disorders. 2018. Milan, Italy.

Kempton C, Recht M, Neff A, Wang M, Buckner T, Soni A, Quon D, Witkop M, Boggio L and Cooper DL. Impact of pain and functional impairment in US adult people with hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. 57th Annual Meeting of the American Society of Hematology. 2015. Orlando, FL.

Kesselheim JC, Agrawal A, Bhatia N, Cronin A, Jurban R, Kent P, Kersun L, Nageswara A, Rose M, Savelli S, Sharma M, Shereck E, Twist C and Wang M. Humanism and Professionalism Training in Pediatric Hemoatology-Oncology Fellowship: Results of a Randomized Trial. 31st Annual Meeting of the American Society of Pediatric Hematology/Oncology. 2018. Pittsburgh, PA.

Hernandez G, Baumann K, Wang M, Recht M, Owens W, Kempton CL and Cooper DL. Functional impairment in adults with mild-to-severe hemophilia: insights from the Hemophilia Experiences, Results and Opportunities (HERO), Pain, Functional Impairment, and Quality of Life (P-FiQ), and Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) studies. XXXIII International Congress of the World Federation of Hemophilia. 2018. Glasgow, Scotland.

Kerlin B, Kulkarni R, Nolan B, Wang M, John Pasi K, Liesner R, Brown S, Hanabusa H, Pabinger-Fasching I, Tsao E and Allen G. Long-term efficacy of rFVIIIFC Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A. 57th Annual Meeting of the American Society of Hematology. 2015. Orlando, FL.

Warren BB, Thornhill D, Shearer R, Ries C, Wang M, Buckner TW and Manco-Johnson MJ. Influence of Age of Prophylaxis Initiation on Hemophilia Joint Health Scores in Severe Hemophilia A. XXXIII International Congress of the World Federation of Hemophilia. 2018. Glasgow, Scotland.

Buckner TW, Thornhill D, Shearer R, Ries C, Wang M, Warren BB and Manco-Johnson MJ. Increased Severity of Joint Disease in Individuals with Hemophilia A Compared to Hemophilia B as Measured by the Hemophilia Joint Health Score. XXXIII International Congress of the World Federation of Hemophilia. 2018. Glasgow, Scotland.

Munn JE, Rajpurkar M, Patel K, Journeycake J, Sharathkumar A, Wang M, Watson CD, McCarthy EG, Cheng D, DeSancho M, and Jaffray J. Transition of Care for Pediatric Patients with Venous Thromboembolism. 62nd Annual SSC Meeting of the International Society on Thrombosis and Haemostasis. 2018. Dublin, Ireland.

Young G, Lieser L, Sidonio R, Oldenberg J, Jimenez-Juste V, Mahlangu J, Kruse-Jarres R, Wang M, Chang T, Uguen M, Doral M, Schmitt C, Levy G, Shima M and Mancuso ME. Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia A with Inhibitors: Results from the HAVEN 2 Study. 60th Annual Meeting of the American Society of Hematology. 2018. San Diego, CA.

Carcao M, Shapiro A, Hwang N, Pipe S, Ahuja S, Belletrutti M, Lieuw K, Stabler J, Sun HL, Ding H, Wang M, Steele M, Tsao E, Feng J, Al-Khateeb Z, Dumont J and Jain N. Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure. 60th Annual Meeting of the American Society of Hematology. 2018. San Diego, CA.

Ambruso DR, Nuss R and Wang M. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 23rd Edition. McGraw-Hill Education, Lange. 2018.

Wang M, Konkle BA, Sidonio R, Flood V, Koenig C and Kulkarni R. Von Willebrand Disease Outreach into Integrated Care Education (VOICE): a call to action. Haemophilia (in press)

Croteau SE, Callahan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M and Iorio A. Focusing in on use of PK profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018;00:1–8.

Batt K, Boggio L, Neff, Anne; Buckner TW, Wang M, Quon D, Witkop M, Recht M, Kessler C, Iyer NN and Cooper DL. Patient-Reported Outcomes and Joint Status Across Subgroups of US Adults With Hemophilia With Varying Characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Eur J Haemotol. 2018;100:14-24.

Buckner TW, Batt K, Quon D, Witkop M, Recht M, Kessler C, Baumann K, Hernandez G, Wang M, Cooper DL and KemptonCL. Assessments of Pain, Functional Impairment, Anxiety, and Depression in US Adults With Hemophilia Across Patient-Reported Outcome Instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Eur J Haemotol. 2018;100:5-13.

Kempton C, Recht M, Neff A, Wang M, Buckner TW, Amit S, Quon D, Witkop M, Boggio L, Gut R and Cooper DL. Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ). Haemophilia. 2018;24(2):261-270.

Young G, Lieser L, Chang T, Sidonio R, Oldenberg J, Jimenez-Juste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Schmitt C, Levy GG, Shima M and Mancuso ME. A multicentre, open-label, non-randomised phase 3 study of emicizumab prophylaxis in children with haemophilia A with inhibitors. Blood 2019 (in press)

Wang M, Peltier S, Baumann K, Sidonio RF, Witkop M, Cooper DL, Waters EK and Kahan S. Awareness, Care, and Treatment in Obesity Management to Inform Hemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a Survey of US Hemophilia Treatment Center Professionals. Haemophilia. 2019 (in press)

Wang M, Recht M, Iyer NN, Cooper DL and Soucie JM. The Relationship of Joint Range of Motion to Factor Activity in Patients with Hemophilia A and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset. Res Pract Thromb Haemost. (in press)

Santoro C, Wang M, Fuh B, Maes P, Minot Castellano ME, Berrueco R, Rauchensteiner S and Le PQ. TAURAS Real-world study: Straightforward Transition to BAY 81-8973 Prophylaxis in Patients with Haemophilia A with Maintained or Reduced Dosing Frequency. 12th Annual Congress of the European Association of Haemophilia and Allied Disorders. 2019. Prague, Czech Republic.

Santoro C, Fuh B, Maes P, Mingot Castellano ME, Berrueco R, Le PQ, Rauchensteiner S and Wang M. Determinants of Prophylaxis Regimen Choice for Patients with Hemophilia A Switching to BAY 81-8973: Real World Findings from the TAURUS Non-Interventional Study. 12th Annual Congress of the European Association of Haemophilia and Allied Disorders. 2019. Prague, Czech Republic.

Young G, Lieser L, Sidonio R, Oldenberg J, Jimenez-Juste V, Mahlangu J, Kruse-Jarres R, Wang M, Chang T, Uguen M, Doral M, Schmitt C, Levy G, Shima M and Mancuso ME. HAVEN 2: Emicizumab Prophylaxis for children with hemophilia A and inhibitors. 59th Annual meeting of the British Society of Haematology. 2019. Glasgow, Scotland.

Wang M, Chrisentery-Singleton T, Tarantino MD, Saad H and Kreilgaard. Modeling dosing active pateints with turoctocog alfa – a rFVIII with extended temperature stability. Hemostasis and Thrombosis Research Society Research Symposium. 2019. New Orleans, LA.

Wang M, Peltier S, Baumann K, Sidonio R, Wadden T, Witkop M, Cooper DL, Ostrow V and Kahan S. Awareness, Care, and Treatment in Obesity Management to inform Hemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a survey of United States (US) Hemophilia Treatment Center (HTC) Professionals. Hemostasis and Thrombosis Research Society Research Symposium. 2019. New Orleans, LA.

Carcao M, Shapiro A, Hwang N, Pipe S, Ahuja S, Belletrutti M, Lieuw K, Stabler J, Sun HL, Ding H, Wang M, Steele M, Tsao E, Feng J, Al-Khateeb Z, Dumont J and Jain N. Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure. Hemostasis and Thrombosis Research Society Research Symposium. 2019. New Orleans, LA.

Shapiro A, Chaudhury A, Wang M, Escobar M, Jain N, Tsao E, Barnowski C, Fend J and Quon DV. Real-world data on the use of rFIXFc demonstrated improved bleed control and adherence with reduced treatment burden. Hemostasis and Thrombosis Research Society Research Symposium. 2019. New Orleans, LA.

Malec L, Carcao M, Jain N, Spasova M, Konstantinov D, Bhatager N, Sharathkumar A, Rodriguez N, Hwang N, Chan A, Wang M, Van Damme A, Wright J, Haya S, Tsao E, Reuter C, Lethagen S and Peyvandi F. Interim Results on time to tolerization using rFVIIIFc for first-time immune tolerance induction (ITI) therapy from the global, prospective verITI-8 study. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2019. Melbourne, Australia.

Lasky J, Teitel J, Wang M, Dalton D, Schmidt DS and Brainsky A. Efficacy and safety of fibrinogen concentrate for treatment of bleeding, surgery or routine prophylaxis in subjects with congenital fibrinogen deficiency. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2019. Melbourne, Australia.

Wang M, Simpson M, Boggio L, Mead H, Balasa V and Davis J. Real-world consumption rFVIII single chain: US population experience. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2019. Melbourne, Australia.

Mahlangu J, Lamas JL, Morales JC, Malan DR, Zupancic-Salek S, Wang M, Boggio LN, Hegemann I, Mital A, Cardinal M, Zhu T, Sun P and Arkin S. A Phase 1b/2 Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PF-06741086, an anti-TFPI Monoclonal Antibody, in Patients with Severe Hemophilia A or B. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2019. Melbourne, Australia.

Phu Quoc P, Maes P, Castellano EM, Berrueco R, Wang M, Fuh B, Solms A, Vis P, Hooijmaijers R, Rauchensteiner S and Santoro C. Pharmacokinetic properties of BAY 81-8973: Real-world data from TAURUS non-interventional study. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2019. Melbourne, Australia.

Manco-Johnson M, Thornhill D, Wang M, Boulden Warren B, Ng C, Branchford B, Di Paola J, Ruegg K, Baird C, Jacobson L, Kamyab Hesari N and Smith T. Predictors of recurrence and post thrombotic syndrome (PTS) following lower extremity deep vein thrombosis in children and adolescents: PTS risk reduction using thrombolysis as initial therapy. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2019. Melbourne, Australia.

Manco-Johnson M, Jones K, O’Neil P, Wang M, Boulden Warren B, Davison-Castillo P, Ng C, Branchford B, Walker F, Smith J, Kamyab Hesari N, Gao B and Di Paola J. Enriched variants of coagulation, platelet and related genes are common in adolescents with idiopathic occlusive proximal deep vein thrombosis. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2019. Melbourne, Australia.

Manco-Johnson M, Wang M, Boulden Warren B, Buckner T, Moyer G, Jacobson L, Ruegg K, Ng C, Branchford B and Di Paola J. Emicizumab improves factor X activation and thrombin generation similar to mild hemophilia in persons with hemophilia A and inhibitors. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2019. Melbourne, Australia.

Malec L, Carcao M, Jain N, Spasova M, Konstantinov D, Bhatager N, Sharathkumar A, Rodriguez N, Hwang N, Chan A, Wang M, Van Damme A, Wright J, Haya S, Tsao E, Reuter C, Lethagen S and Peyvandi F. rFVIIIFc for first-time immune tolerance induction (ITI) therapy: interim results from the global, prospective verITI-8 study. 10th Bari International Congress. 2019. Genoa, Italy.

Wheeler AP, Wang M, Chrisentery-Singleton T, Chitlur, Kreilgaard M, Cooper, DL and Miguel Escobar M.. Modeling of Daily Administration of N8-GP (ESPEROCT®) vs Standard Half-Life FVIII for Patients with Hemophilia A Participating in Sports Activities. 71st Annual Meeting of the National Hemophilia Foundation. 2019. Anaheim, CA.

Malec L, Carcao M, Jain N, Spasova M, Konstantinov D, Bhatager N, Sharathkumar A, Rodriguez N, Hwang N, Chan A, Wang M, Van Damme A, Wright J, Haya S, Tsao E, Reuter C, Lethagen S and Peyvandi F. rFVIIIFc for first-time immune tolerance induction therapy: interim results from the global, prospective verITI-8 study. 71st Annual Meeting of the National Hemophilia Foundation. 2019. Anaheim, CA.

Wang M, McKinney C, Ambruso DR and Nuss R. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 23rd Edition. McGraw-Hill Education, Lange.

Manco-Johnson MJ, Warren BB, Buckner TB, Funk S and Wang M. Outcome measures: Beyond ABR. Haemophilia. 2020. (in press)

Croteau SE, Wang M and Wheeler AP. 2020 Clinical Trials Update: Innovations in Hemophilia Therapy. Am J Hematol. 2020;1-17.

Maher KN, Gibson E, Warren BB, Funk S, Shearer R, Buckner T, Wang M, Manco-Johnson M and Ng CJ. Prophylaxis for Children with Moderate Hemophilia: Use of a Guideline to Increase Early Initiation. Pediatr Blood Cancer. 2020;e28577.

Walsh C, Coppens M, Escobar M and Wang M. Optimal trough levels in hemophilia B: Raising expectations. Haemophilia. 2020.

Carcao M, Shapiro A, Hwang N, Pipe S, Ahuja S, Lieuw K, Stabler J, Belletrutti M, Sun HL, Ding H, Wang M, Price V, Steele M, Tsao E, Feng J, Al-Khateeb Z, Dumont J and Jain N. Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Patients with Severe Haemophilia A with Inhibitors at High Risk for ITI Failure: A Follow-up Retrospective Analysis. Haemophilia. Haemophilia. 2020.

Wang M, Peltier S, Baumann K, Sidonio RF, Witkop M, Cooper DL, Waters EK and Kahan S. Awareness, Care, and Treatment in Obesity Management to Inform Hemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a Survey of US Hemophilia Treatment Center Professionals. Haemophilia. 2020;26 Suppl 1:20-30.

Santoro C, Fuh B, Phu QL, Maes P, Berrueco RM, Mingot-Castellano, von Mackensen, Solms A and Wang M. BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A from real-world observation: interim results from the TAURUS study. Eur J Haemotol. 2020;105(2):164-172.

Wang M, Recht M, Iyer NN, Cooper DL and Soucie JM. The Relationship of Joint Range of Motion to Factor Activity in Patients with Hemophilia A and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset. Res Pract Thromb Haemost. 2020;4(6):1035-1045.

Lasky J, Teitel J, Wang M, Dalton D, Schmidt DS and Brainsky A. Efficacy and safety of fibrinogen concentrate for treatment of bleeding, surgery or routine prophylaxis in subjects with congenital fibrinogen deficiency. Res Pract Thromb Haemost. 2020;00:1-11.

Shapiro A, Chaudhury, Wang M, Escobar M, Tsao E, Barnowski C, Feng J, Jain N and Quon DV. Real-world data demonstrates improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. Haemophilia. 2020;26(6):975-983.

Le PQ, Maes P, Castellano EM, Berrueco R, Wang M, Fuh B, Soto A and Santoro C. BAY 81-8973 prophylaxis in patients with haemophilia A: interim findings for children <12 years from the TAURUS real-world study. EAHAD. The Hague, Netherlands. 2020.

Chan A, Warren BB, Ng C, Buckner TW, Moyer G, Furton L, Branchford B, Manco-Johnson M and Wang M. Influence of emicizumab on patient lifestyle at the University of Colorado. XXXIV International

Santoro C, Wang M, Fuh B, Maes P, Mingot-Castellano M-E, Berrueco R, Detering E & Le PQ. BAY 81-8973 prophylaxis in patients with hemophilia A: interim usage and safety results from the TAURUS real-world study. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.

Roberts JC, Escobar M, Acharya S, Hwang NX, Wang M, Hale S, Oladapo A, S Asghar and Kouides PA. Retrospective Chart Review of Gastrointestinal Bleeding in Patients with von Willebrand Disease: study design and initial demographic results. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.

Hermans C, Journeycake J, Ducore J, Escobar M, Young G, Wang M, Quon D, Alexander WA, Mitchell I, Al-Sabbagh and Bonzo D. The single dose efficacy of eptacog beta (recombinant human factor VIIa variant) when modeled over time challenges the practice of repeated low doses when treating bleeds in hemophilia patients with inhibitors. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.

Buckner T, Daoud N, Croteau SE, Kempton CL, Malec L, Stabler J, Wang M, Watson C and Recht M. ATHN 7: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Hemophilia-Demographics and Preliminary Results. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.

Boulden Warren B, Thornhill D, Smith J, Shearer R, Jacobson L, Moyer G, Fox L, O’Connor M, Horton R, Funk S, Chan A, Ng C, Buckner TW, Branchford B, Manco-Johnson MJ and Wang M. Emicizumab, beyond Annualized Bleeding Rates: Real World Joint Health and Physical Activity Data. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.

Moyer G, Boulden Warren B, Jacobson L, Baird C, Thornhill D, Smith J, Ng C, Buckner TW, Branchford B, Wang M and Manco-Johnson MJ. Emicizumab, beyond ABR: can we predict Emi effects from laboratory assays? XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.

Branchford B, Ng C, Boulden Warren B, Taylor J, Ambruso D, Briones N, Tran A, Jacobson L, Thornhill D, Moyer G, Norton K, Buckner TB, Wang M and Manco-Johnson MJ. Emicizumab, beyond ABR: what does Emi do to bones? XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.

Buckner TW, Rapacchietta O, Hill D, Thornhill D, Smith J, Shearer R, Ng C, Branchford B, Moyer G, Manco-Johnson M, Wang M. Improved Prophylaxis Adherence After Switching to Emicizumab: Real-World Data from a Single Center. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.

Buckner T, Carpenter SL, Croteau SE, Cuker A, Daoud N, Kempton CL, Malec L, McLean TW, Raffini L, Stabler J, Wang M, Watson C, Zia A and Recht M. Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B. 62nd American Society of Hematology Annual Meeting. 2020.

Journeycake J, Hermans C, Ducore J, Escobar M, Young G, Wang M, Quon D, Alexander WA, Mitchell I, Al-Sabbagh and Bonzo D. Single 225µg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia ? or ? with Inhibitors: A PERSEPT1 Subset Analysis. 62nd American Society of Hematology Annual Meeting. 2020.

Roberts JC, Escobar M, Acharya S, Hwang NX, Wang M, Hale S, Oladapo A, S Asghar, Mehdi S and Kouides PA. Retrospective Chart Review of Gastrointestinal Bleeding in Patients with von Willebrand Disease. 62nd American Society of Hematology Annual Meeting. 2020.

Escobar M, Quon D, Wang M, Warren B, Wufus A and Ostrow V. Surgical Procedures in Patient with Hemophilia: Multi-Stakeholder Perspectives from 2018 Round Tables. 62nd American Society of Hematology Annual Meeting. 2020.

Pipe SW, Recht M, Key NS, Leebeek FWG, Castaman G, Lattimore S, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi KJ, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Bajwa N, Gut R, Miesbach W. First data from the Phase 3 HOPE-B gene therapy trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B. 62nd American Society of Hematology Annual Meeting. 2020.

DeSancho MT, Munn J, Billet HH, ZCheng D, Holmes C, Jaffray J, Malone M, Patel K, Sharathkumar A, Thornburg CD, Wang M, Watson C, Rajpurkar M. "Transition of Care for Pediatric and Adult Patients with Venous Thromboembolism: A National Quality Improvement Project from the American Thrombosis and Hemostasis Network (ATHN). Thromb Res. 2021 Apr;200:23-29. doi: 10.1016/j.thromres.2021.01.001. Epub 2021 Jan 18. PMID: 33517168

Ng C, Spomer N, Shearer R, LeBlanc A, Funk S, Manco-Johnson M, Branchford B, Warren B, Buckner T, Moyer G, Wang M, Gibson E and Mashburn C. Quality Improvement Initiative to Improve Communication and Coordination of Care in a Hemophilia Treatment Center. Acta Haematol. 2021 Apr 29:1-6. doi: 10.1159/000515350. Online ahead of print. PMID: 33915533

Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S; Kids_DOTT Trial Investigators and the Atlas Group. JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182. PMID: 35015038

Buckner TW, Kleiboer B, Layer M, Cafuir L, Cuker A, Escobar M, Eyster E, Kraut E, Leavitt A, Lentz S, Quon D, Ragni M, Thornhill D, Wang M and Key Nigel. Buckner TW. Prospective, multicenter observational study of postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery. J Thromb Haemost. 2022 Apr;20(4):857-865. doi: 10.1111/jth.15654. PMID: 35080347

Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Haroon Mitha I, Negrier C, Nowak-Gottl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Villarreal Martinez L, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkeinson TA and Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in pediatric subjects (<12 years) with hemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27. doi: 10.1111/hae.14563.

Leebeek FWG, Peyvandi F, Escobar M, Tiede A, Castaman G, Wang M, Wynn T, Baptista J, Wang Y, Zhang J, Mellgard B, and Ozen G. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood. 2022 Apr 19:blood.2021014810. doi: 10.1182/blood.2021014810. PMID: 35439298.

Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt A, Laffan, Symington E, Quon DQ, Wang J-D, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O’Mahoney B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B, GENEr8-1 Trial Group. Valoctocogene Roxaparvovec Gene Therapy in Hemophilia A. N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi: 10.1056/NEJMoa2113708. PMID: 35294811

Wang M, Negrier C, Driessler F, Goodman C and Skinner M. Hemophilia gene therapying the context of the patient journey. Patient Prefer Adherence. 2022 Jun 9;16:1439-1447. doi: 10.2147/PPA.S355627.eCollection 2022.

Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA and Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects ( <12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Jul;28(4):548-556. doi: 10.1111/hae.14563.Epub 2022 Apr 27.

Mahlangu JN, Lamas JL, Moralews JC, Malan DR, Zupancic-Salek S, Wang M, Boggio LN, Hegemann I, Mital A, Cardinal M, Zhu T, Sun P and Arkin S. Marstacimab, a human tissue factor pathway inhibitor, for severe hemophilia. (in press, Br J Haematol.)

Warren BB, Chan A, Manco-Johnson M, Branchford BR, Buckner TW, Moyer G, Gibson E, Thornhill D, Wang M and Ng CJ. Emicizumab Initiation and Bleeding Outcomes in Hemophilia A Patients with and without Inhibitors, a Single-Center Report. Res Pract Thromb Haemost. 2021 Aug 3;5(5):e12571. doi: 10.1002/rth2.12571.eCollection 2021 Jul.

Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou S-C, Ozelo C, Kenet G, Peyvandi F, Wang M, Madan B, Key NS, Laffan M, Dunn AL, Mason J, Quon DQ, Symington E, Leavitt A, Oldenburg J, Chambost H, Reding MT, Jayaram K, Yu H, Mahajan R, Chavele K-M, Reddy DB, Henshaw J, Robinson TM, Wong WY and Pipe SW. Two-year Safety and Efficacy of Valoctocogene Roxaparvovec Gene Therapy in Hemophilia A. (in press, NEJM)

Maher KN, Gibson E, Warren BB, Funk SM, Shearer R, Buckner TW, Wang M, Manco-Johnson MJ and Ng CJ. Prophylaxis for children with moderate hemophilia: Use of a guideline to increase early initiation. Pediatr Blood Cancer. 2021 Jan;68(1):e28577. doi: 10.1002/pbc.28577. Epub 2021 Sep 2.

Holsteen PE, Meier M, Brennan L, VanHorn T, Voinescu C, Kuldanek S, Wang M and Martiniano SL. Safety and effectiveness of a risk-stratified venous thromboembolism prophylaxis algorithm in patients with cystic fibrosis. Thromb Res. 2021 Oct;206:36-41. doi: 10.1016/j.thromres.2021.07.007. Epub 2021 Jul 10. PMID: 34399123

Witkop M, Wang M, Hernandez G, Recht M, Baumann K and Cooper DL. Impact of hemophilia on patients with mild-to-moderate disease: results from the P-FiQ and B-HERO-S studies. Haemophilia. 2021 Jan;27 Suppl 1:8-16. doi: 10.1111/hae.14251. PMID: 33522654

Escobar M, Callaghan M, Ducore J, Hermans C, Journeycake J, Lessinger C, Luck J, Mahlangu J, Quon D, Recht M, Schved J-F, Shapiro A, Sidonio R, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Wilkinson TA and Kessler C. The Safety of Activated Eptacog Beta in the Management of Bleeding Episodes and Perioperative Hemostasis in Adult and Pediatric Hemophilia Patients with Inhibitors. Haemophilia. 2021;27:921-931.

Escobar M, Luck J, Averianov Y, Lopez Fernandez MF, Giermasz A, Hart D, Journeycake J, Craig Kessler, Leissinger C, Mahlangu J, Villarreal Martinez L, Miesbach W, Haroon Mitha I, Quon D, Reding M, Schved J-F, Stasyshyn O, Vilchevska KV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell I, Wilkinson TA and Hermans C. PERSEPT 3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia A or B with Inhibitors. Haemophilia. 2021;27:911-920.

Carcao M, Shapiro A, Hwang N, Pipe S, Ahuja S, Lieuw K, Stabler J, Belletrutti M, Sun HL, Ding H, Wang M, Price V, Steele M, Tsao E, Feng J, Al-Khateeb Z, Dumont J and Jain N. Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Patients with Severe Haemophilia A with Inhibitors at High Risk for ITI Failure: A Follow-up Retrospective Analysis. Haemophilia. 2021 Jan;27(1):19-25. doi: 10.1111/hae.14192. Epub 2020 Nov 18.

Pipe SW, Recht M, Key NS, Leebeek FWG, Castaman G, Lattimore S, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi KJ, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Gut R, Miesbach W. First Phase 3 Gene Therapy Trial for Hemophilia B: Successful Treatment Despite Neutralizing Antibodies to Adeno-associated Virus. (in press, NEJM)

Wang M, Nuss R and McKinney C. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 24rd Edition. McGraw-Hill Education, Lange. 2022.

Hermans C, Mahlangu J, Ahuja S, Carcao M, Castaman G, Davis J, Hart D, Khan O, Miesbach W, Nowak-Gottl U, Reding M, Schved F-F, Villarreal Martinez L, Wang M, Windyga J, Witkop M, Young G, Bonzo D, Mitchell I and Kessler C. Pain relief with eptacog beta in haemophilia patients with inhibitors. EAHAD. 2022. Virtual.

Hermans C, Mahlangu J, Ahuja S, Carcao M, Castaman G, Davis J, Hart D, Khan O, Miesbach W, Nowak-Gottl U, Reding M, Schved F-F, Villarreal Martinez L, Wang M, Windyga J, Witkop M, Young G, Bonzo D, Mitchell I and Kessler C. Pain relief with eptacog beta in haemophilia patients with inhibitors. XXXV International Congress of the World Federation of Hemophilia. Montreal. 2022.

Nowak-Gottl U, Young G, Pipe S, Hermans C, Carcao M, Castaman G, Davis J, Ducore J, Dunn A, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha IH, Negrier C, Recht M, Singleton T, Stasyshyn O, Vilchevska K, Villarreal Martinez L, Wang M, Wingyga J, Bonzo D, Macie C, Wilkinson T and Shapiro A. Analysis of bleeding episode resolution with eptacog beta by age group in young patients with hemophilia A or B with inhibitors. 66th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Leipzig, Germany. 2022.

Hermans C, Miesbach W, Journeycake J, Ducore J, Escobar M, Wang M, Quon D, Cisse OA, Chambron N, Mitchell IS, Al-Sabbagh A, Bonzo D and Mahlangu J. High dose eptacog beta (factor VIIa, recombinant) is effective in the treatment of bleeding episodes regardless of severity in adult and adolescents with hemophilia A or B with inhibitors. EAHAD. 2021. Manchester, UK.

Pipe SW, Recht M, Key NS, Leebeek FWG, Castaman G, Lattimore S, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi KJ, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Bajwa N, Gut R, Miesbach W. Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderate-Severe Hemophilia B: First data from the phase 3 HOPE-B gene therapy trial. EAHAD. 2021. Manchester, UK.

Escobar M, Callaghan M, Ducore J, Hermans C, Journeycake J, Lessinger C, Luck J, Quon D, Recht M, Schved JF, Sidonio R, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Wilkenson T and Kessler C. The Safety of Activated Eptacog Beta in Hemophilia Patients with Inhibitors in Adult, Pediatric, and Surgical Settings. Hemostasis and Thrombosis Research Society Research Symposium. 2021. Virtual.

Pipe S, Callaghan M, Ducore J, Escobar M, Hermnans C, Journeycake J, Meeks S, Recht M, Wang M, Young G, WA Alexander, Al-Sabbagh A, Bonzo D, Mitchell and Shapiro A. Evaluation of the hemostatic efficacy of eptacog beta (recombinant factor VIIa) for the treatment of bleeding in pediatric subjects (<12 years) with hemophilia A or B with inhibitors in PERSEPT 2. Hemostasis and Thrombosis Research Society Research Symposium. 2021. Virtual.

Roberts JC, Escobar E, Acharya S, Hwang NX, Wang M, Hale S, Asghar S and Kouides PA. Gastrointestinal bleeding in patients with von Willebrand disease: treatments and outcomes. Hemostasis and Thrombosis Research Society Research Symposium. 2021. Virtual.

Escobar M, Quon D, Wang M, Wufus A, Ostrow V and Warren B. Surgical procedures in patients with hemophilia: Multistakeholder perspectives from 2018 roundtables. Hemostasis and Thrombosis Research Society Research Symposium. 2021. Virtual.

Pipe SW, Ozelo MC, Kenet G, Reding M, Mason J, Leavitt AD, Madan B, Laffan M, Quon DV, von Drygalski A, Chou S-C, Shapiro S, Dunn A, Nunez R, Wang M, Key NS, Kaczmarek R, Syminton E, Mahajan R, Chavale K-M, Reddy D, Wong WY, Robinson TM and Kim B. Relationship between endogenous, transgene FVIII expression and bleeding events following valoctocogene roxaparvovec gene transfer for severe hemophila A: a post-hoc analysis of the GENEr8-1 phase 3 trial. 66th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Leipzig, Germany. 2022.

Miesbach W, Kessler C, Windyga J, Hart D, Villarreal Martinez L, Schved J-F, Mahlangu J, Acharya S, Ahuja S, Ducore J, Escobar M, Carcao M, Castaman G, Hermans C, Quon D, Sidonio R, Reding M, Singleton T, Wang M, Bonzo D, Macie C and Nowak-Gottl U. Comparing 225 µg/kg to 75 µg/kg dosing regimens across pivotal clinical trials. 66th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Leipzig, Germany. 2022.

Leebek FW, Miesbach W, Recht M, Key NS, Lattimore S, Castaman G, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi J, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemoins R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Cooper D, Ferriera V and Pipe SW. Clinical outcomes in adults with hemophilia B with and without pre-existing neutralizing antibodies to AAV5: 6-month data from the phase 3 etranacogene dezaparvovec HOPE-B gene therapy trial. European Hematology Association Congress. 2021. Virtual.

Buckner TW, Carpenter SL, Kempton CL, Lee L, Malec L, McLean TW, Morton P, Stabler JM, Wang M and Recht M. Safety and Efficacy of Emicizumab in People with Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7). XXVIII Congress of the International Society on Thrombosis and Haemostasis. London, UK. 2022.

Lemons R, Wang M, Curtin J, Huth-Kuehne A, Lepatan LM, Male C, Peyvandi F, vo Depka Prondzinski M, D McKeand, Seifert W and Oldenburg J. Safety and Efficacy of Recombinant Factor IX Fusion Protein (rIX-FP) in Previously Untreated Patients with Hemophilia B. XXVIII Congress of the International Society on Thrombosis and Haemostasis. London, UK. 2022.

Castaman G, Pipe SW, Callaghan M, Ducore J, Escobar M, Hermans C, Mahlangu J, Nowak-Gottl U, Journeycake J, Khan O, Meeks S, Recht M, Wang M, Young G, Chambron N, Al-Sabbagh A, Bonzo D, Mitchell IS and Shapiro A. Activated Eptacog-beta, w rFVIIa, is effective and safe in the treatment of bleeding episodes of all severities in pediatric hemophilia A or B patients with inhibitors. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual.

Mahlangu J, Escobar M, Callaghan M, Ducore J, De Moerloose, Hermans PC, Castaman G, Schved -F, Journeycake J, Leissinger C, Luck J, Quon D, Recht, Sidonio, Srivastava A, Wang M, Young G, Al-Sabbagh A, Bonzo D, Chambron N, Wilkinson T and Kessler C. The Safety of Activated Eptacog Beta in Hemophilia Patients with Inhibitors in Adult, Pediatric, and Perisurgical Settings. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual.

Wang M, Siffel C, Turecek P, Gazda H, Fung S, Swallow E, Greatsinger A, Billmyer E and Hertfelder H-J. Real-world treatment of severe congenital protein C deficiency with protein C concentrate including prophylaxis: A physician survey in Europe and the US. XXVIII Congress of the International Society on Thrombosis and Haemostasis. London, UK. 2022.

Mahlangu J, Chambost H, Chou S-C, Dunn A, von Drygalski A, Kaczmarek R, Kenet G, Key NS, Laffan M, Leavitt AD, Madan, B, Mason J, Oldenburg J, Ozelo MC, Peyvandi F, Quon DV, Reding MT, Shapiro S, Symington E, Wang M, Yu H, Mahajan R, Chavele K-M, Reddy D, Robinson T, Pipe SW. Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1. XXVIII Congress of the International Society on Thrombosis and Haemostasis. London, UK. 2022.

Young G, Sidonio R, Oldenburg J, Jiménez Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Shima M, Tzeng E, Ko RH, Bernardi R, Fox R, and Mancuso ME. Bleed prevention and safety in children on every 2 week and every 4 week emicizumab prophylaxis: 52-week outcomes in HAVEN 2. Annual Meeting of the National Hemophilia Foundation. 2022.

Kessler C, Abajas Y, Acharya.S, Ahuja S, Chitler M, Giermasz A, Khan O, Mauer K, Danielle N, Rafique A, Reding MT, Chrisentary-Singleton T, Tran DQ, Witkop M, Young G, Bonzo D, Mavie C, Wilkerson TA, and Wang M. Pain relief with eptacog beta in hemophilia patients with inhibitors. Annual Meeting of the National Hemophilia Foundation. 2022.

Leebeek FWG, Escobar M, Tiede A, Wang M, Zulfikar B, Wang S, Wang Y, and Ozen G. Prophylaxis with Recombinant von Willebrand factor in Patients with Type 3 von Willebrand disease: Post Hoc Analysis from a Phase 3 Trial. Thrombosis & Hemostasis Summit of North America. Chicago, IL. 2022.

Pipe SW, Callaghan M, Ducore J, Escobar M, Hermans C, Journeycake J, Meeks S, Recht M, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell I, and Shapiro A. Evaluation of the hemostatic efficacy of eptacog beta (recombinant factor VIIa) for the treatment of bleeding in pediatric subjects (<12 years) with hemophilia A or B with inhibitors in PERSEPT 2. Thrombosis & Hemostasis Summit of North America. Chicago, IL. 2022.

Escobar M, Callaghan M, Ducore J, Hermans C, Journeycake J, Lessinger C, Luck J, Quon D, Recht M, Schved J-F, Sidonio R, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Wilkenson T, and Kessler C. The Safety of Activated Eptacog Beta in Hemophilia Patients with Inhibitors in Adult, Pediatric, and Surgical Settings. Thrombosis & Hemostasis Summit of North America. Chicago, IL. 2022.

Carpenter SL, Chandler M, Guerrera M, Malec L, Manuel M, Recht M, Reiss UM, Sidonio R, Tarango C, van den Berg M, Wang M, Thornburg C on behalf of the ATHN 8 investigators. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor development and treatment characteristics. 64th American Society of Hematology Annual Meeting. New Orleans, LA. 2022.

Reding M, Mancuso ME, Acharya S, Ahuja S, Alvarez-Roman MT, Boggio L, Chitlur M, Majluf Cruz A, Dunn A, Escobar M, Harroche A, Janbain M, Kessler C, Maes P, McGuinn C, Nance D, Nowk-Gottl, Sidonio R, Tran D, Wang M, Wingyda J, Wang H, Wilkenson T, and Pipe S. Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1. 64th American Society of Hematology Annual Meeting. New Orleans, LA. 2022.

Quon DV, Wang JD, Wang M, Pepperell D, Park YS, Kenet G, Mahlangu J, Khoo T-L, Robinson TM, Chavele K-M, and Pipe S. Relationship Between Endogenous FVIII Activity and Bleeding Episodes Resulting from Procedures: A Post Hoc Analysis of the GENEr8-1 Phase 3 Trial. 64th American Society of Hematology Annual Meeting. New Orleans, LA. 2022.

Leebeek FWG, Peyvandi F, Tiede A, Castaman G, Escobar M, Wang M, Zulfikar B, Susen S, Miesbach W, Wang S, Wang Y, ZhangWynn T, Baptista J, Wang Y, Zhang J, and Ozen G. Prophylaxis with recombinant von Willebrand factor (rVWF) in patients with type 3 von Willebrand disease (VWD): results of a post-hoc analysis from a phase 3 trial. Eur J Haematol. 2023 Feb 23. doi: 10.1111/ejh.13949. Online ahead of print. PMID: 36823994

Pipe SW, Recht M, Key NS, Leebeek FWG, Castaman G, Lattimore S, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi KJ, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Gut R, Miesbach W. First Phase 3 Gene Therapy Trial for Hemophilia B: Successful Treatment Despite Neutralizing Antibodies to Adeno-associated Virus. N Engl J Med. 2023 Feb 23;388(8):706-718. doi: 10.1056/NEJMoa2211644.

Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou S-C, Ozelo C, Kenet G, Peyvandi F, Wang M, Madan B, Key NS, Laffan M, Dunn AL, Mason J, Quon DQ, Symington E, Leavitt A, Oldenburg J, Chambost H, Reding MT, Jayaram K, Yu H, Mahajan R, Chavele K-M, Reddy DB, Henshaw J, Robinson TM, Wong WY and Pipe SW. Two-year Safety and Efficacy of Valoctocogene Roxaparvovec Gene Therapy in Hemophilia A. N Engl J Med. 2023 Feb 23;388(8):694-705. doi: 10.1056/NEJMoa2211075. PMID: 36812433

Santoro C, Fuh B, Le PQ, Maes P, Berrueco R, Mingot-Castellano EM, von Mackensen S, Tueckmantel C, Cabre Marquez JF and Wang M. Efficacy and safety in patients with haemophilia A switching to Kovaltry (BAY 81-8973): Final results of the global real-world study, TAURAS. Eur J Haematol. 2023 Jan;110(1):77-87. doi: 10.1111/ejh.13876. Epub 2022 Oct 17. PMID: 36192847

McKinney C, Nakano T, Forrester C, Nuss N and Wang M. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 25rd Edition. McGraw-Hill Education, Lange.

Mahlangu JN, Lamas JL, Moralews JC, Malan DR, Zupancic-Salek S, Wang M, Boggio LN, Hegemann I, Mital A, Cardinal M, Zhu T, Sun P and Arkin S. Treatment with marstacimab for people with severe hemophilia A or B: a plain language summary of the results from a short-term study and a longer-term study. Future Rare Dis. 10.2217/frd-2023-0004.

Hermans C, Miesbach W, Journeycake J, Ducore J, Escobar M, Wang M, Quon D, Cisse OA, Chambron N, Mitchel. IS, Al-Sabbagh A, Bonzo D, and Mahlangu J. High dose of Eptacog Beta (Factor VIIa, Recombinant) is effective in the treatment of bleeding episodes regardless of severity in adult and adolescent with Hemophilia A or B with Inhibitors. 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Germany. 2023.

Lemons R, Wang M, Curtin J, Lepatan LM, Male C, Peyvandi F, Von Depka Prondzinski M, Wang R, McKeand W, Seifert W, and Oldenburg J. Safety and Efficacy of Recombinant Factor IX Fusion Protein (rIX-FP) in Previously Untreated Patients with Haemophilia B. 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Germany. 2023.

Quon DV, Wang JD, Wang M, Pepperell D, Park YS, Klamroth R, Kenet G, Mahlangu J, Khoo T-L, Robinson TM, Chavele K-M, and Pipe SW. Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1. 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Germany. 2023.

Quon DV, Wang JD, Wang M, Pepperell D, Park YS, Kenet G, Mahlangu J, Khoo T-L, Robinson TM, Chavele K-M, and Pipe SW. Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1. EAHAD. Manchester, U.K. 2023.

Chowdary P, Khoo L, Wang M, Chambost H, Chan AKC, Moryusef A, Willemze A, and Oldenburg J. Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A. XXVIV Congress of the International Society on Thrombosis and Haemostasis. Montreal, Canada. 2023.

Buckner TW, Daoud N, Lee L, Morton P, O’Neill C, Wang M, and Recht M. Emicizumab prophylaxis in people with hemophilia A aged =50 years with comorbidities: experience from the ATHN 7 hemophilia natural history study. XXVIV Congress of the International Society on Thrombosis and Haemostasis. Montreal, Canada. 2023.

Mann K, Wang M, Roybal J. When One Chronic Disease Obscures Another: Gait Changes in a Patient with Hemophilia B. American Academy for Cerebral Palsy and Developmental Medicine Annual Meeting. Chicago, IL. 2023.

Quon DV, Wang JD, Wang M, Pepperell D, Park YS, Kenet G, Mahlangu J, Khoo T-L, Robinson TM, Chavele K-M, and Pipe SW. Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1. 56th Nordic Coagulation Meeting. 2023. Oslo, Norway.

Miesbach W, Hermans C, Pipe SW, Journeycake J, Ducore J, Escobar M, Wang M, Quon D, Boggio L, Chambron N, Mitchell IS, Al-Sabbagh A, Bonzo D and Mahlangu J. Activated Eptacog Beta (Factor VIIa, Recombinant) Provides Rapid Bleed Resolution and Pain Relief in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual.

Buckner TW, Kleiboer B, Layer M, Cafuir L, Cuker A, Escobar M, Eyster E, Kraut E, Leavitt A, Lentz S, Quon D, Ragni M, Thornhill D, Wang M and Key Nigel. Prospective, multicenter observational study of postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual

Warren BB, Thornhill D, Jacobson L, Baird C, Hill D, Ng C, Buckner T, Wang M and Manco-Johnson M. Emicizumab: What can patients expect regarding hemostasis, bleeding and sports capacity? XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual.

Pipe SW, Ozelo MC, Kenet G, Reding M, Mason J, Leavitt AD, Madan B, Laffan M, Quon DV, von Drygalski A, Chou S-C, Shapiro S, Dunn A, Nunez R, Wang M, Key NS, Kaczmarek R, Syminton E, Mahajan R, Chavale K-M, Reddy D, Wong WY, Robinson TM and Kim B. Relationship between endogenous, transgene FVIII expression and bleeding events following valoctocogene roxaparvovec gene transfer for severe hemophila A: a post-hoc analysis of the GENEr8-1 phase 3 trial. American Society of Hematology Annual Meeting. Atlanta, GA. 2021.

Young G,Pipe SW, Hermans C, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha IH, Negrier C, Nowak-Gottl U, Recht M, Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Wang H, Macie C, Mitchell IS, Wilkerson TA and Shapiro AD. Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age. American Society of Hematology Annual Meeting. Atlanta, GA. 2021.

Journeycake J, Raffini L, Sidonio R, Chrisentery-Singleton T, Wang M, von Drygalski A, Cheng D, Recht M, Fedor, Hirsh N and Neufeld E. Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study. American Society of Hematology Annual Meeting. Atlanta, GA. 2021.

Wheat E, Dunham BM, Tedeschi W, Richfield K, Spomet N, Gibson E, Blue A, Regier M, Wang M, Buckner TW. Feasibility of Delivering Transition Education During Annual Comprehensive Clinic Appointments and Patient-Reported Outcomes: A Quality Improvement Study. American Society of Hematology Annual Meeting. Atlanta, GA. 2021.

Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation

Medical School

Undergraduate School

Residency

Fellowships

Languages

Department

Recognitions

Research Interests

Publications

Professional Memberships

Practice Locations

Specialty Information

School of Medicine

CU Anschutz

Fitzsimons Building